共 50 条
Cancer Incidence and Mortality According to Pre-Existing Heart Failure in a Community-Based Cohort
被引:50
|作者:
Bertero, Edoardo
[1
,2
,3
]
Robusto, Fabio
[4
]
Rulli, Eliana
[5
]
D'Ettorre, Antonio
[6
]
Bisceglia, Lucia
[7
]
Staszewsky, Lidia
[6
]
Maack, Christoph
[3
]
Lepore, Vito
[6
]
Latini, Roberto
[6
]
Ameri, Pietro
[1
,2
]
机构:
[1] IRCCS Osped Policlin San Martino, Italian IRCCS Cardiol Network, Cardiovasc Dis Unit, Genoa, Italy
[2] Univ Genoa, Dept Internal Med, Genoa, Italy
[3] Univ Clin Wurzburg, Comprehens Heart Failure Ctr, Wurzburg, Germany
[4] Azienda Sanit Locale TA, Medonline Statte, Taranto, Italy
[5] Ist Ric Farmacol Mario Negri IRCCS, Methodol Clin Res Lab, Dept Oncol, Milan, Italy
[6] Ist Ric Farmacol Mario Negri IRCCS, Dept Cardiovasc Med, Milan, Italy
[7] Reg Hlth Agcy Puglia, Epidemiol & Care Intelligence Area, Bari, Italy
来源:
关键词:
cardio-oncology;
comorbidity;
cancer;
heart failure;
mortality;
CARDIOVASCULAR-DISEASE;
INCREASED RISK;
TUMOR-GROWTH;
HOSPITALIZATION;
ASSOCIATION;
INFARCTION;
SURVIVORS;
D O I:
10.1016/j.jaccao.2021.11.007
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
BACKGROUND Studies assessing whether heart failure (HF) is associated with cancer and cancer-related mortality have yielded conflicting results.OBJECTIVES This study assessed cancer incidence and mortality according to pre-existing HF in a community-based cohort.METHODS Among individuals $50 years of age from the Puglia region in Italy with administrative health data from 2002 to 2018, no cancer within 3 years before the baseline evaluation, and $5-year follow-up, the study matched 104,020 subjects with HF at baseline with 104,020 control subjects according to age, sex, drug-derived complexity index, Charlson comorbidity index, and follow-up duration. Cancer incidence and mortality were defined based on International Classification of Diseases-Ninth Revision codes in hospitalization records or death certificates.RESULTS The incidence rate of cancer in HF patients and control subjects was 21.36 (95% CI: 20.98-21.74) and 12.42 (95% CI: 12.14-12.72) per 1000 person-years, respectively, with the HR being 1.76 (95% CI: 1.71-1.81). Cancer mortality was also higher in HF patients than control subjects (HR: 4.11; 95% CI: 3.86-4.38), especially in those <70 years of age (HR: 7.54; 95% CI: 6.33-8.98 vs HR: 3.80; 95% CI: 3.44-4.19 for 70-79 years of age; and HR: 3.10; 95% CI: 2.81-3.43 for $80 years of age). The association between HF and cancer mortality was confirmed in a competing risk analysis (subdistribution HR: 3.48; 95% CI: 3.27-3.72). The HF-related excess risk applied to the majority of cancer types. Among HF patients, prescription of high-dose loop diuretic was associated with higher cancer incidence (HR: 1.11; 95% CI: 1.031.21) and mortality (HR: 1.35; 95% CI: 1.19-1.53). CONCLUSIONS HF is associated with an increased risk of cancer and cancer-related mortality, which may be heightened in decompensated states. (J Am Coll Cardiol CardioOnc 2022;4:98-109) (c) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:98 / 109
页数:12
相关论文